Alflutinib

Drug Profile

Alflutinib

Alternative Names: Alflutinib mesylate; AST-2818

Latest Information Update: 01 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Allist Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Non-small cell lung cancer

Most Recent Events

  • 02 May 2017 Allist Pharmaceuticals plans a clinical trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease, In operable/Unresectable, Recurrent, Second-line therapy or greater) (NCT03127449)
  • 30 Nov 2016 Allist Pharmaceuticals plans a phase I trial for Non-small cell lung cancer in China (NCT02973763)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top